EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Phase II randomised, placebo-controlled, clinical trial of interleukin-1 receptor antagonist in intracerebral haemorrhage: BLOcking the Cytokine IL-1 in ICH (BLOC-ICH)

Adrian R Parry-Jones iD, Katie Stocking, Mary Joan MacLeod, Brian Clarke, David J Werring, Keith W Muir, Andy Vail

European Stroke Journal · 01.09.2023 · 8 (3) · 819-827

DOI: 10.1177/23969873231185208 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Stroke Journal, online erschienen am 01.09.2023. Verfasst von Adrian R Parry-Jones und 6 weiteren Autor:innen. Beteiligte Einrichtung: Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance & University of Manchester, Manchester, U…. Hauptthemen laut MEDLINE: Interleukin 1 Receptor Antagonist Protein, Cytokines. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: EPA, Department of Health, Research Trainees Coordinating Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Recombinant human interleukin-1 receptor antagonist (anakinra) is an anti-inflammatory with efficacy in animal models of stroke. We tested the effect of anakinra on perihaematomal oedema in acute intracerebral haemorrhage (ICH) and explored effects on inflammatory markers.

Methods

We conducted a multicentre, randomised, double-blind, placebo-controlled trial in patients with acute, spontaneous, supratentorial ICH between May 2019 and February 2021. Patients were randomised to 100 mg subcutaneous anakinra within 8 h of onset, followed by five, 12-hourly, 100 mg subcutaneous injections, or matched placebo. Primary outcome was oedema extension distance (OED) on a 72 h CT scan. Secondary outcomes included plasma C-reactive protein (CRP) and interleukin-6 (IL-6).

Findings

25 patients (target = 80) were recruited, 14 randomised to anakinra, 11 to placebo. Mean age was 67 and 52% were male. The anakinra group had higher median baseline ICH volume (12.6 ml, interquartile range[IQR]:4.8–17.9) versus placebo (5.5 ml, IQR:2.1–10.9). Adjusting for baseline, 72 h OED was not significantly different between groups (mean difference OED anakinra vs placebo -0.05 cm, 95% confidence interval [CI]: −0.17–0.06, p = 0.336). There was no significant difference in area-under-the-curve to Day 4 for IL-6 and CRP, but a post-hoc analysis demonstrated IL-6 was 56% (95% CI: 2%–80%) lower at Day 2 with anakinra. There were 10 and 2 serious adverse events in anakinra and placebo groups, respectively, none attributed to anakinra.

Conclusion

We describe feasibility for delivering anakinra in acute ICH and provide preliminary safety data. We lacked power to test for effects on oedema thus further trials will be required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin 1 Receptor Antagonist ProteinCytokinesHumansMaleAgedFemaleInterleukin-6Cerebral HemorrhageInterleukin InhibitorsReceptors, Interleukin-1Interleukin-1

Stichwörter der Autor:innen

Intracerebral haemorrhageanakinraclinical trialinterleukin-1 receptor antagonist

Substanzen

Interleukin 1 Receptor Antagonist ProteinCytokinesInterleukin-6Interleukin InhibitorsReceptors, Interleukin-1Interleukin-1

Autor:innen und Institutionen

  • Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance & University of Manchester, Manchester, UK.
  • Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Centre for Biostatistics, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • The Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.
  • Department of Stroke Medicine, St George's University Hospitals NHS Foundation Trust, London, UK.
  • Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, London, UK.

ORCID-Profile: Adrian R Parry-Jones

Förderung

  • EPA
  • Department of Health
  • Research Trainees Coordinating Centre

Zitieren

APA

Parry-Jones, A. R., Stocking, K., MacLeod, M. J., Clarke, B., Werring, D. J., Muir, K. W., & Vail, A. (2023). Phase II randomised, placebo-controlled, clinical trial of interleukin-1 receptor antagonist in intracerebral haemorrhage: BLOcking the Cytokine IL-1 in ICH (BLOC-ICH). European Stroke Journal, 8(3), 819-827. https://doi.org/10.1177/23969873231185208

Vancouver

Parry-Jones AR, Stocking K, MacLeod MJ, Clarke B, Werring DJ, Muir KW, et al. Phase II randomised, placebo-controlled, clinical trial of interleukin-1 receptor antagonist in intracerebral haemorrhage: BLOcking the Cytokine IL-1 in ICH (BLOC-ICH). European Stroke Journal. 2023;8(3):819-827. doi:10.1177/23969873231185208

BibTeX
@article{ParryJones2023,
  author = {Parry-Jones, Adrian R and Stocking, Katie and MacLeod, Mary Joan and Clarke, Brian and Werring, David J and Muir, Keith W and Vail, Andy},
  title = {Phase II randomised, placebo-controlled, clinical trial of interleukin-1 receptor antagonist in intracerebral haemorrhage: BLOcking the Cytokine IL-1 in ICH (BLOC-ICH)},
  journal = {European Stroke Journal},
  year = {2023},
  volume = {8},
  number = {3},
  pages = {819--827},
  doi = {10.1177/23969873231185208}
}
Kostenlos starten →